Marinus pharmaceuticals inc (MRNS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Expenses:
Research and development

42,966

28,394

12,376

22,005

18,916

8,690

4,150

General and administrative

11,456

8,785

6,667

6,237

5,516

3,230

1,229

Loss from operations

-54,422

-37,179

-19,043

-28,242

-24,432

-11,920

-5,379

Interest income

354

454

324

128

64

-

-

Change in fair value of warrant liability

-

-

-

-

-

-1,192

-153

Interest income

-

-

-

-

-

12

47

Interest expense

-

-

159

464

475

117

91

Other expense

-53

-1

-20

-65

-7

-

-

Net loss

-54,121

-36,726

-18,898

-28,643

-24,850

-10,833

-5,270

Cumulative preferred stock dividends

-

-

-

-

-

2,545

3,804

Net loss applicable to common shareholders

-

-

-

-

-

-13,378

-9,074

Per share information:
Net loss per share of common stock—basic and diluted

-0.99

-0.90

-0.80

-1.47

-1.67

-2.17

-19.60

Basic and diluted weighted average shares outstanding

54,512

40,895

23,540

19,498

14,919

6,152

462

Net loss

-54,121

-36,726

-18,898

-28,643

-24,850

-

-

Other comprehensive income (loss):
Unrealized gain on available-for-sale securities

-

94

-96

-

-

-

-

Total comprehensive loss

-54,121

-36,632

-18,994

-28,643

-24,850

-

-